In both trials , patients in the control arm received docetaxel/cisplatin ; in the experimental arm , patients with low RAP@ expression received gemcitabine/cisplatin , those with intermediate/high RAP@ expression and low/intermediate BRCA@ expression received docetaxel/cisplatin , and those with intermediate/high RAP@ expression and high BRCA@ expression received docetaxel alone .